Navigation Links
STAAR Surgical To Present At The Benchmark And Jefferies Investor Conferences
Date:5/29/2012

MONROVIA, Calif., May 29, 2012 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it  will participate in two upcoming investor conferences to review the Company's recent financial results and current business developments with investors and interested parties.

The Benchmark Company One-on-One Investor Conference will be held on Thursday, May 31, 2012 at the Pfister Hotel in Milwaukee, Wisconsin.  Barry G. Caldwell, President and CEO, and Deborah Andrews, CFO, will meet with interested investors in a series of one-on-one meetings.

This Benchmark Company Investor Conference does not provide for companies to webcast the event; however, a copy of the Company's Conference presentation will be available at the Company's website, www.staar.com, under Investor Information. Investors planning to attend the conference should contact their Benchmark representative to arrange a meeting.

The Company will also present at the Jefferies 2012 Global Healthcare Conference in New York on Thursday, June 7, 2012 at 3:00 p.m. ET.  Barry G. Caldwell, President and CEO, Deborah Andrews, CFO, and Sam Gesten, General Counsel, will be attending the conference.

STAAR will offer a live video webcast of its presentation on the Company's website, www.staar.com, under Investor Information. An archived replay of the presentation will be available for 30 days, also at www.staar.com.

About STAAR SurgicalSTAAR, which has been dedicated solely to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye.  All of these lenses are foldable, which permits the surgeon to insert them through a small incision.  STAAR's lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer® Lens or "ICL."  A lens used to replace the natural lens after cataract surgery is called an intraocular lens or "IOL."  Over 300,000 Visian ICLs have been implanted to date; to learn more about the ICL go to: www.visianinfo.com.
STAAR has approximately 300 full time employees and markets lenses in approximately 50 countries.  Headquartered in Monrovia, CA, it manufactures in the following locations: Nidau, Switzerland; Ichikawa City, Japan; Aliso Viejo, CA; and Monrovia, CA.  For more information, please visit the Company's website at www.staar.com or call 626-303-7902. 

Collamer® is the registered trademark for STAAR's proprietary biocompatible collagen copolymer lens material.  CONTACT: Investors

Media EVC Group

EVC GroupDouglas Sherk, 415-652-9100

Chris GaleJenifer Kirtland, 415-568-9349

646-201-5431


'/>"/>

SOURCE STAAR Surgical Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York
2. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
3. STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter
4. STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS
5. STAAR Surgical Reports Continued Double Digit Core Revenue Growth
6. STAAR Surgicals Visian® ICL Surpasses 200,000 Implants
7. STAAR Surgical Announces Fourth Quarter 2010 Revenue Expected to Exceed $14.2 Million
8. STAAR Surgical Enters Into Distribution Agreement With Ellex in Australia
9. STAAR Surgical Launches Second Phase of Visian ICL Direct-to-Consumer Advertising Campaign
10. STAAR Surgicals nanoFLEX™ Collamer® IOL Receives CE Mark Approval
11. STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Südkorea, 23. Februar 2017 LG Innotek ... Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls ... Strahlung im Bereich zwischen 200 und 280 nm und eignet ... Bakterien, indem es ihre DNA zerstört. Das Produkt von ... ...
(Date:2/23/2017)... Feb. 23, 2017 ITL Limited, ( ASX: ITD ), ... for the half year ended 31 December 2016 compared with the ... presentation can be viewed here . Highlights ... $1.04m; up 104%) Earnings per share of 2.2 ... of $17.5m (Dec 2015: $15.7m; up 11%) Profit ...
(Date:2/23/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - 2016, provides ... research answers the following questions: What are ... they positioned in the Global Menopause market? What are ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... 2017 , ... Occupational pesticide exposure is linked to an ... according to a study released today at the 1st Pan American Parkinson’s and ... pesticides and incidence of sporadic PD through occupational exposure. This latest study, led ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... replacement options at his office, Antoine Dental Center. Currently, patients can get single ... restrictions may apply, but patients can learn more about these offers by contacting ...
(Date:2/24/2017)... , ... February 24, 2017 , ... An in-depth computational ... the University of Pittsburgh points to eight genes that may explain why susceptibility to ... to the results of a study published today in the journal npj Schizophrenia. ...
(Date:2/24/2017)... ... , ... In the Health Care IT campaign, Robert Herjavec discusses health IT ... you will be attacked, but when.” However, he and many others involved highlight a ... Improvements in auditing and monitoring have taken security in health care a very long ...
(Date:2/24/2017)... ... , ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” ... paramedic experiences. Schanssema describes the tragedies he saw, as well as his struggles with ... Schanssema, initially unsure of the career path he wanted to take, found fulfillment in ...
Breaking Medicine News(10 mins):